ATE444953T1 - Substituierte spirobenzazepine - Google Patents

Substituierte spirobenzazepine

Info

Publication number
ATE444953T1
ATE444953T1 AT04809449T AT04809449T ATE444953T1 AT E444953 T1 ATE444953 T1 AT E444953T1 AT 04809449 T AT04809449 T AT 04809449T AT 04809449 T AT04809449 T AT 04809449T AT E444953 T1 ATE444953 T1 AT E444953T1
Authority
AT
Austria
Prior art keywords
spirobenzazepines
substituted
substituted spirobenzazepines
Prior art date
Application number
AT04809449T
Other languages
English (en)
Inventor
Mona Patel
Philip Rybczynski
Min Xiang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE444953T1 publication Critical patent/ATE444953T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT04809449T 2003-06-17 2004-06-16 Substituierte spirobenzazepine ATE444953T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47937803P 2003-06-17 2003-06-17
PCT/US2004/019460 WO2005037795A2 (en) 2003-06-17 2004-06-16 Substituted spirobenzazepines

Publications (1)

Publication Number Publication Date
ATE444953T1 true ATE444953T1 (de) 2009-10-15

Family

ID=34465052

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04809449T ATE444953T1 (de) 2003-06-17 2004-06-16 Substituierte spirobenzazepine

Country Status (30)

Country Link
US (2) US20040266752A1 (de)
EP (1) EP1633719B1 (de)
JP (1) JP5252614B2 (de)
KR (1) KR101086246B1 (de)
CN (1) CN100467454C (de)
AR (1) AR044782A1 (de)
AT (1) ATE444953T1 (de)
AU (1) AU2004281257C1 (de)
BR (1) BRPI0411598A (de)
CA (1) CA2529649C (de)
CL (1) CL2004001507A1 (de)
CR (1) CR8168A (de)
CY (1) CY1109585T1 (de)
DE (1) DE602004023501D1 (de)
DK (1) DK1633719T3 (de)
EA (1) EA011089B1 (de)
ES (1) ES2332724T3 (de)
HR (2) HRP20090606T1 (de)
IL (1) IL172630A (de)
ME (1) ME00320B (de)
NO (1) NO20060247L (de)
NZ (1) NZ544180A (de)
PL (1) PL1633719T3 (de)
PT (1) PT1633719E (de)
RS (1) RS20050930A (de)
SI (1) SI1633719T1 (de)
TW (1) TWI354555B (de)
UA (1) UA82236C2 (de)
WO (1) WO2005037795A2 (de)
ZA (1) ZA200600430B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007516177A (ja) * 2003-06-17 2007-06-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 非ペプチド置換スピロベンゾアゼピン誘導体の製造方法
CA2637838A1 (en) * 2006-01-20 2007-07-26 Janssen Pharmaceutica N.V. Novel solid forms of (4r)-1-¬4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl|-1,2,3,5-tetrahydro-spiro¬4h-1-benzazepine-4,1'-¬2|cyclopentene|-3'-carboxylic acid
PT2078022E (pt) * 2006-09-22 2012-01-11 Janssen Pharmaceutica Nv Espiro benzazepinas utilizadas como antagonistas de vasopressina
JP2010504352A (ja) * 2006-09-22 2010-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ バソプレッシン拮抗薬としてのスピロベンズアゼピン類
AR066834A1 (es) * 2007-06-06 2009-09-16 Janssen Pharmaceutica Nv Espirobenzoazepanos como antagonistas de vasopresina, composiciones farmaceuticas que los contienen, proceso de preparacion y usos para el tratamiento de afecciones cardiacas, renales y del sistema nervioso central.
CA2705097A1 (en) * 2007-11-07 2009-05-14 Janssen Pharmaceutica N.V. Combination therapy comprising angiotensin converting enzyme inhibitors and vasopressin receptor antagonists
WO2014062888A1 (en) 2012-10-18 2014-04-24 University Of South Florida Compositions and methods for treating stroke
JP5968466B2 (ja) 2012-12-26 2016-08-10 株式会社三和化学研究所 新規ベンゾアゼピン誘導体及びその医薬用途
TW202246273A (zh) * 2021-03-05 2022-12-01 大陸商上海濟煜醫藥科技有限公司 新型苯并氮雜卓并環衍生物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617302A (en) 1984-10-15 1986-10-14 Eli Lilly And Company Inotropic agents
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5985869A (en) * 1989-10-20 1999-11-16 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
DK0450097T3 (da) 1989-10-20 1996-05-20 Otsuka Pharma Co Ltd Benzoheterocykliske forbindelser
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5849780A (en) 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
WO1994007496A1 (en) * 1992-10-07 1994-04-14 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
WO1995028930A1 (en) * 1994-04-22 1995-11-02 Pentech Pharmaceuticals, Inc. Dosage forms and method for ameliorating male erectile dysfunction
US5753648A (en) * 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
JP3282494B2 (ja) * 1995-05-16 2002-05-13 富士ゼロックス株式会社 画像定着装置
US5753715A (en) 1995-06-02 1998-05-19 Ortho Pharmaceutical Corporation 2-disubstituted cyclohexenyl and cyclohexyl antimicrobial agents
US5726723A (en) * 1996-01-31 1998-03-10 Technology Research International Corporation Sub-twisted nematic liquid crystal display
AUPP150098A0 (en) 1998-01-27 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
US7001898B2 (en) * 2000-07-05 2006-02-21 Ortho-Mcneil Pharmaceutical, Inc. Nonpeptide substituted spirobenzoazepines as vasopressin antagonists
JP2007516177A (ja) * 2003-06-17 2007-06-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 非ペプチド置換スピロベンゾアゼピン誘導体の製造方法

Also Published As

Publication number Publication date
MEP49108A (en) 2011-02-10
SI1633719T1 (sl) 2010-01-29
TW200515911A (en) 2005-05-16
KR20060023157A (ko) 2006-03-13
JP2007521272A (ja) 2007-08-02
AR044782A1 (es) 2005-10-05
AU2004281257B2 (en) 2010-02-04
EA200501831A1 (ru) 2006-06-30
ES2332724T3 (es) 2010-02-11
CR8168A (es) 2008-09-10
ZA200600430B (en) 2009-08-26
NZ544180A (en) 2009-01-31
TWI354555B (en) 2011-12-21
US20070179128A1 (en) 2007-08-02
IL172630A0 (en) 2006-04-10
HRP20090606T1 (hr) 2010-01-31
EA011089B1 (ru) 2008-12-30
RS20050930A (sr) 2008-04-04
HRP20051006A2 (en) 2006-05-31
BRPI0411598A (pt) 2006-08-29
US7687494B2 (en) 2010-03-30
CA2529649A1 (en) 2005-04-28
DE602004023501D1 (de) 2009-11-19
WO2005037795A2 (en) 2005-04-28
AU2004281257C1 (en) 2010-07-01
IL172630A (en) 2011-10-31
CA2529649C (en) 2012-01-31
KR101086246B1 (ko) 2011-11-23
PL1633719T3 (pl) 2010-03-31
DK1633719T3 (da) 2010-01-04
ME00320B (me) 2011-05-10
JP5252614B2 (ja) 2013-07-31
CN100467454C (zh) 2009-03-11
EP1633719A2 (de) 2006-03-15
US20040266752A1 (en) 2004-12-30
NO20060247L (no) 2006-03-13
CY1109585T1 (el) 2014-08-13
AU2004281257A1 (en) 2005-04-28
EP1633719B1 (de) 2009-10-07
CL2004001507A1 (es) 2005-05-27
PT1633719E (pt) 2009-11-11
UA82236C2 (en) 2008-03-25
CN1835925A (zh) 2006-09-20
WO2005037795A3 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
ATE363383T1 (de) Schlingenware
IS2875B (is) Pýrasólópýridínafleiður
DE502004001683D1 (de) Kabelführung
AT502792A5 (de) Düsenanpressvorrichtung
DE502004007911D1 (de) Wischblatt
DE112004000620D2 (de) Struktoguss
DE10355350A8 (de) Elektromodul
DE502004008321D1 (de) Bandaufwickelverfahren
ATA662003A (de) Trink-mundstück
DE502004001524D1 (de) Hydrolager
ATE446959T1 (de) Chromenonindole
DE502004002978D1 (de) N-biarylamide
DE502004001629D1 (de) Bremsenprüfstand
DK1633719T3 (da) Substituerede spirobenzazepiner
DE502004003122D1 (de) Hydrolager
DE502004009935D1 (de) Substituierte dihydrochinazoline ii
DE112004002227D2 (de) Nietverarbeitungsgerät
DE502004005162D1 (de) Leistungsregelvorricthung
DE502004006563D1 (de) Brieftaubenkonstatiersystem
DE10394329D2 (de) Mäanderstent
DE10329218B4 (de) Hotflue
ATE406350T1 (de) Prolinylarylacetamide
DE502004007251D1 (de) En 2-arylpropenalen
DE502004002771D1 (de) Umlenkhebel
DE112004001561D2 (de) Getriebene-Antreibseinheit

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1633719

Country of ref document: EP